Literature DB >> 12613468

Bringing managed care home to people with chronic, disabling conditions: prospects and challenges for policy, practice, and research.

Dennis L Kodner1, Corinne Kay Kyriacou.   

Abstract

This article examines the challenges and opportunities inherent in the idea that home care organizations may be able to reinvent themselves into managed care systems for the frail elderly and chronically ill. Data come from three sources: (a) existing literature, (b) a survey with experts, and (c) insights from an organization with direct experience in designing and implementing first- and second-generation managed care programs. The authors conclude that although even the best-positioned home care organizations will face significant challenges in transitioning to managed care systems (e.g., establishing medical linkages, building managed care capacity, securing funding, dealing with regulatory hurdles), changes in the environment may enable these challenges to be overcome. Home care organizations are beginning to use innovative techniques to manage care, and those with a strong commitment to the chronically ill may be interested and capable of pursuing the option of becoming home-based managed chronic care programs.

Entities:  

Mesh:

Year:  2003        PMID: 12613468     DOI: 10.1177/0898264302239024

Source DB:  PubMed          Journal:  J Aging Health        ISSN: 0898-2643


  3 in total

Review 1.  Transitional care.

Authors:  Mary Naylor; Stacen A Keating
Journal:  Am J Nurs       Date:  2008-09       Impact factor: 2.220

2.  Consumer-directed services: lessons and implications for integrated systems of care.

Authors:  Dennis L Kodner
Journal:  Int J Integr Care       Date:  2003-06-17       Impact factor: 5.120

3.  A framework for understanding outcomes of integrated care programs for the hospitalised elderly.

Authors:  Jacqueline M Hartgerink; Jane M Cramm; Jeroen D H van Wijngaarden; Ton J E M Bakker; Johan P Mackenbach; Anna P Nieboer
Journal:  Int J Integr Care       Date:  2013-11-28       Impact factor: 5.120

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.